Part II, Section 3, Sub-section (ii) of the Gazette
of India, Extraordinary
National Pharmaceutical Pricing Authority: New
Delhi, the 29th March, 2019
ORDER
SO:…. In continuation of the notifications issued
by National Pharmaceutical Pricing Authority, Department of
Pharmaceuticals, Ministry of Chemical and Fertilizers vide S.O. 639(E) dated
12.02.2018 and S.O. 1464(E) dated 02.04.2018, regarding the
fixation of ceiling price of the
Coronary Stents as specified in column no. (2) mentioned in the table
below; after considering the Wholesale Price
Index (WPI) @ 4.2662 percent for the year 2018 over 2017, it
has been decided to revise the ceiling prices of Coronary Stents as mentioned
in column no. (4) in the table below, exclusive of Goods and Services Tax as
applicable, and unit specified in column (3) with effect from 01.04.2019, as
under:
Table
|
Sl No
|
Coronary Stents
( Sl No. 31 in Schedule-I of the DPCO, 2013)
|
Unit
(in Number)
|
Ceiling Price
(in Rs.)
|
|
(1)
|
(2)
|
(3)
|
(4)
|
|
1
|
Bare Metal Stents
|
1
|
8,261
|
|
2
|
Drug Eluting Stents (DES) including metallic DES
and Bioresorbable Vascular Scaffold (BVS)/ Biodegradable Stents
|
1
|
30,080
|
a) All the existing manufacturers/importers of Coronary Stents
having MRP lower than the ceiling price specified in column (4) in the above
table (plus Goods and Services Taxes as applicable, if any), may revise the
existing MRP of Coronary Stent, on the basis of WPI @ 4.2662% for year 2018 in
accordance with Paragraph 16(2) of DPCO, 2013, read with Para 13(2) of DPCO,
2013.
b) The manufacturers/importers of Coronary Stents may add
Goods and Services Taxes only if they have paid actually or if it is payable to
the Government on the ceiling price mentioned in column (4) of the aforesaid
table.
c) As per Para 24(4) of DPCO 2013, every retailer and
dealer shall display price list and the supplementary price list, if any, as
furnished by the manufacturer/importers, on a conspicuous part of the premises
where he carries on business in a manner so as to be easily accessible to any
person wishing to consult the same.
d) The manufacturers not complying with the ceiling price
and notes specified hereinabove shall be liable to deposit the overcharged
amount along with interest thereon under the provisions of the Drugs (Prices
Control) Order, 2013 read with Essential Commodities Act, 1955.
PN/197/65/2019/F / F. No.
8(65)/2019/D.P./NPPA-Div.-II /ALOK RANJAN/ Assistant Director
Dr KK Aggarwal
Padma Shri Awardee
President Elect Confederation of
Medical Associations in Asia and Oceania
(CMAAO)
Group Editor-in-Chief IJCP Publications
President Heart Care Foundation of
India
Past National President
IMA
No comments:
Post a Comment